Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment
Clinical trial NCT06106802 · RECRUITING
Trial details
- NCT number
- NCT06106802
- Sponsor
- Samsung Medical Center
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-06-11
- Primary completion
- 2029-09-30
- Enrollment
- 47
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.